These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 38714556)

  • 1. [Cystic fibrosis in childhood and adulthood].
    Syunyaeva Z; Mall MA; Stahl M
    Inn Med (Heidelb); 2024 Jun; 65(6):538-544. PubMed ID: 38714556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evidence-based treatment of cystic fibrosis].
    Ringshausen FC; Hellmuth T; Dittrich AM
    Internist (Berl); 2020 Dec; 61(12):1212-1229. PubMed ID: 33201261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
    Derichs N
    Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New treatments targeting the basic defects in cystic fibrosis.
    Fajac I; Wainwright CE
    Presse Med; 2017 Jun; 46(6 Pt 2):e165-e175. PubMed ID: 28554723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Update on cystic fibrosis : From neonatal screening to causal treatment].
    Sommerburg O; Wielpütz MO
    Radiologie (Heidelb); 2022 Nov; 62(11):981-994. PubMed ID: 36278998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.
    O'Reilly R; Elphick HE
    Drug Des Devel Ther; 2013; 7():929-37. PubMed ID: 24039402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A foetus with cystic fibrosis - To treat or not to treat?
    Padmakumar N; Khan HS
    Respir Med Res; 2023 Jun; 83():101006. PubMed ID: 37037055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of cystic fibrosis in adulthood and eligibility for novel CFTR modulator therapy.
    Farley H; Poole S; Chapman S; Flight W
    Postgrad Med J; 2022 May; 98(1159):341-345. PubMed ID: 33452147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Patients with cystic fibrosis become adults : Treatment hopes and disappointments].
    Eschenhagen P; Schwarz C
    Internist (Berl); 2019 Jan; 60(1):98-108. PubMed ID: 30627755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis.
    Taylor-Cousar JL; Shteinberg M; Cohen-Cymberknoh M; Jain R
    Clin Ther; 2023 Mar; 45(3):278-289. PubMed ID: 36841738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystic fibrosis.
    Mall MA; Burgel PR; Castellani C; Davies JC; Salathe M; Taylor-Cousar JL
    Nat Rev Dis Primers; 2024 Aug; 10(1):53. PubMed ID: 39117676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians.
    Terlizzi V; Farrell PM
    Curr Probl Pediatr Adolesc Health Care; 2024 Jun; 54(6):101637. PubMed ID: 38811287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis.
    Schneider-Futschik EK
    Gene Ther; 2019 Sep; 26(9):354-362. PubMed ID: 31300729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic spectrum of patients with cystic fibrosis and cystic fibrosis-related disease carrying p.Arg117His.
    Keenan K; Dupuis A; Griffin K; Castellani C; Tullis E; Gonska T
    J Cyst Fibros; 2019 Mar; 18(2):265-270. PubMed ID: 30279124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.
    Kotha K; Clancy JP
    Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.